JPS58164516A - 湿疹性皮膚疾患および薬疹治療剤 - Google Patents
湿疹性皮膚疾患および薬疹治療剤Info
- Publication number
- JPS58164516A JPS58164516A JP57047880A JP4788082A JPS58164516A JP S58164516 A JPS58164516 A JP S58164516A JP 57047880 A JP57047880 A JP 57047880A JP 4788082 A JP4788082 A JP 4788082A JP S58164516 A JPS58164516 A JP S58164516A
- Authority
- JP
- Japan
- Prior art keywords
- carnosine
- remedy
- injection
- eczema
- powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000017520 skin disease Diseases 0.000 title abstract description 5
- 208000019872 Drug Eruptions Diseases 0.000 title abstract 2
- 108010087806 Carnosine Proteins 0.000 claims abstract description 32
- CQOVPNPJLQNMDC-UHFFFAOYSA-N N-beta-alanyl-L-histidine Natural products NCCC(=O)NC(C(O)=O)CC1=CN=CN1 CQOVPNPJLQNMDC-UHFFFAOYSA-N 0.000 claims abstract description 32
- CQOVPNPJLQNMDC-ZETCQYMHSA-N carnosine Chemical compound [NH3+]CCC(=O)N[C@H](C([O-])=O)CC1=CNC=N1 CQOVPNPJLQNMDC-ZETCQYMHSA-N 0.000 claims abstract description 32
- 150000003839 salts Chemical class 0.000 claims abstract description 8
- 239000004480 active ingredient Substances 0.000 claims abstract description 6
- QRYRORQUOLYVBU-VBKZILBWSA-N Carnosic acid Natural products CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 claims description 13
- 229940044199 carnosine Drugs 0.000 claims description 13
- 208000029648 Eczematous Skin disease Diseases 0.000 claims description 5
- 239000002674 ointment Substances 0.000 abstract description 15
- 239000000843 powder Substances 0.000 abstract description 15
- 239000007924 injection Substances 0.000 abstract description 11
- 238000002347 injection Methods 0.000 abstract description 11
- 239000007864 aqueous solution Substances 0.000 abstract description 3
- 239000002552 dosage form Substances 0.000 abstract description 3
- 210000004185 liver Anatomy 0.000 abstract description 3
- 239000000243 solution Substances 0.000 abstract description 3
- 241001465754 Metazoa Species 0.000 abstract description 2
- 238000000354 decomposition reaction Methods 0.000 abstract description 2
- 210000003205 muscle Anatomy 0.000 abstract description 2
- 239000008247 solid mixture Substances 0.000 abstract description 2
- 230000008018 melting Effects 0.000 abstract 1
- 238000002844 melting Methods 0.000 abstract 1
- 230000009965 odorless effect Effects 0.000 abstract 1
- 230000009967 tasteless effect Effects 0.000 abstract 1
- 201000004624 Dermatitis Diseases 0.000 description 22
- 208000010668 atopic eczema Diseases 0.000 description 18
- 239000003814 drug Substances 0.000 description 15
- 210000003491 skin Anatomy 0.000 description 11
- 229940124597 therapeutic agent Drugs 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 206010020751 Hypersensitivity Diseases 0.000 description 7
- 239000002253 acid Substances 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 206010012438 Dermatitis atopic Diseases 0.000 description 6
- 230000001154 acute effect Effects 0.000 description 6
- 201000008937 atopic dermatitis Diseases 0.000 description 6
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 210000002374 sebum Anatomy 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 4
- 208000003251 Pruritus Diseases 0.000 description 4
- 208000026935 allergic disease Diseases 0.000 description 4
- 230000007815 allergy Effects 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 208000010201 Exanthema Diseases 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 206010033733 Papule Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 229940000635 beta-alanine Drugs 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000003628 erosive effect Effects 0.000 description 3
- 201000005884 exanthem Diseases 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 206010037844 rash Diseases 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- 108010071840 Cytosol nonspecific dipeptidase Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 206010039509 Scab Diseases 0.000 description 2
- 206010040844 Skin exfoliation Diseases 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 150000003863 ammonium salts Chemical class 0.000 description 2
- 229940125715 antihistaminic agent Drugs 0.000 description 2
- 239000000739 antihistaminic agent Substances 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 125000002843 carboxylic acid group Chemical group 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000036461 convulsion Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 229960002885 histidine Drugs 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 230000011514 reflex Effects 0.000 description 2
- 208000008742 seborrheic dermatitis Diseases 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 238000009121 systemic therapy Methods 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- HIXYEIRACBUSON-FJXQXJEOSA-N (2s)-2-(3-aminopropanoylamino)-3-(1h-imidazol-5-yl)propanoic acid;hydrochloride Chemical compound Cl.NCCC(=O)N[C@H](C(O)=O)CC1=CN=CN1 HIXYEIRACBUSON-FJXQXJEOSA-N 0.000 description 1
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 241000283153 Cetacea Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 206010015535 Euphoric mood Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- BXRMEWOQUXOLDH-LURJTMIESA-N L-Histidine methyl ester Chemical compound COC(=O)[C@@H](N)CC1=CN=CN1 BXRMEWOQUXOLDH-LURJTMIESA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000282330 Procyon lotor Species 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010039792 Seborrhoea Diseases 0.000 description 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 208000033809 Suppuration Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 206010043994 Tonic convulsion Diseases 0.000 description 1
- 206010057970 Toxic skin eruption Diseases 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000000729 antidote Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 229910052785 arsenic Inorganic materials 0.000 description 1
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 238000010531 catalytic reduction reaction Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 210000000078 claw Anatomy 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000011257 definitive treatment Methods 0.000 description 1
- 230000035618 desquamation Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000003256 environmental substance Substances 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 230000002743 euphoric effect Effects 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 210000003746 feather Anatomy 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 239000008311 hydrophilic ointment Substances 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 210000002445 nipple Anatomy 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 235000018343 nutrient deficiency Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 239000003883 ointment base Substances 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000036387 respiratory rate Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 125000005270 trialkylamine group Chemical group 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 210000003905 vulva Anatomy 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP57047880A JPS58164516A (ja) | 1982-03-25 | 1982-03-25 | 湿疹性皮膚疾患および薬疹治療剤 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP57047880A JPS58164516A (ja) | 1982-03-25 | 1982-03-25 | 湿疹性皮膚疾患および薬疹治療剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS58164516A true JPS58164516A (ja) | 1983-09-29 |
| JPH0145451B2 JPH0145451B2 (enrdf_load_stackoverflow) | 1989-10-03 |
Family
ID=12787696
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP57047880A Granted JPS58164516A (ja) | 1982-03-25 | 1982-03-25 | 湿疹性皮膚疾患および薬疹治療剤 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS58164516A (enrdf_load_stackoverflow) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0235057A (ja) * | 1988-04-26 | 1990-02-05 | Kinuko Nagai | 機能性食品 |
| WO2004064866A1 (ja) * | 2003-01-20 | 2004-08-05 | Innovative Vision Products, Inc. | カルノシナーゼ阻害剤とｌ−カルノシン類との併用および組成物 |
| WO2009103959A3 (en) * | 2008-02-20 | 2009-10-15 | The University Of Manchester | Histidine and/or histidine derivative for the treatment of inflammatory skin diseases |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS52131423U (enrdf_load_stackoverflow) * | 1976-03-31 | 1977-10-06 | ||
| JPS56141217U (enrdf_load_stackoverflow) * | 1980-03-25 | 1981-10-24 |
-
1982
- 1982-03-25 JP JP57047880A patent/JPS58164516A/ja active Granted
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS52131423U (enrdf_load_stackoverflow) * | 1976-03-31 | 1977-10-06 | ||
| JPS56141217U (enrdf_load_stackoverflow) * | 1980-03-25 | 1981-10-24 |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0235057A (ja) * | 1988-04-26 | 1990-02-05 | Kinuko Nagai | 機能性食品 |
| WO2004064866A1 (ja) * | 2003-01-20 | 2004-08-05 | Innovative Vision Products, Inc. | カルノシナーゼ阻害剤とｌ−カルノシン類との併用および組成物 |
| EP1586332A1 (en) | 2003-01-20 | 2005-10-19 | Innovative Vision Products, Inc. | Combined use of carnosinase inhibitor with l-carnosines and composition |
| JPWO2004064866A1 (ja) * | 2003-01-20 | 2006-05-18 | イノヴェイティブ ヴィジョン プロダクツ インコーポレーテッド | カルノシナーゼ阻害剤とｌ−カルノシン類との併用および組成物 |
| JP2011068652A (ja) * | 2003-01-20 | 2011-04-07 | Innovative Vision Products Inc | カルノシナーゼ阻害剤とｌ−カルノシン類との併用および組成物 |
| JP2014012735A (ja) * | 2003-01-20 | 2014-01-23 | Innovative Vision Products Inc | カルノシナーゼ阻害剤とｌ−カルノシン類との併用および組成物 |
| WO2009103959A3 (en) * | 2008-02-20 | 2009-10-15 | The University Of Manchester | Histidine and/or histidine derivative for the treatment of inflammatory skin diseases |
| US12350256B2 (en) | 2008-02-20 | 2025-07-08 | Curapel (Scotland) Limited | Histidine and/or histidine derivative for the treatment of inflammatory skin diseases |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0145451B2 (enrdf_load_stackoverflow) | 1989-10-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8426368B2 (en) | Method of ameliorating oxidative stress and supplementing the diet | |
| EP2373346B1 (en) | Ibuprofen for topical administration | |
| KR0145739B1 (ko) | 발포정 | |
| HUE026994T2 (en) | Liquid nasal spray containing low dose naltrexone | |
| WO2010126818A1 (en) | Intranasal delivery system for dantrolene | |
| JPS5938203B2 (ja) | 補酵素ｑを主成分とする脳循環障害治療剤 | |
| US20040127413A1 (en) | Enteric keto acid and amino acid salts and their use for preparing medicines | |
| JPH08295637A (ja) | 口腔部局所投与剤 | |
| JPS58164516A (ja) | 湿疹性皮膚疾患および薬疹治療剤 | |
| JPS6259219A (ja) | 外用鎮咳・去痰・鎮痛・鎮静剤 | |
| JP2002308764A (ja) | 眼科用医薬組成物 | |
| JP3253878B2 (ja) | 鉄キレート化用製剤、その製剤の製法及び地中海貧血症の治療法 | |
| JP5977672B2 (ja) | イブプロフェンリシナートの経口投与用の懸濁液 | |
| CN101057845B (zh) | 草乌甲素干乳剂及其制备方法与应用 | |
| JPS63303931A (ja) | 経鼻投与用成長ホルモン放出活性物質製剤 | |
| CN112439066A (zh) | 包含化学消融剂和pH调节剂的药物组合物及其应用 | |
| JP2003026567A (ja) | 補酵素ｑを有効成分とする粘膜投与用組成物 | |
| JPS58164511A (ja) | 老人性▲そう▼痒症の治療剤 | |
| JPS6045161B2 (ja) | 熱傷の治療剤 | |
| RU2163121C1 (ru) | Средство от простуды | |
| WO2025003464A1 (en) | Composition comprising hinokitiol and zinc salt for use in the treatment of herpes labialis | |
| EA043222B1 (ru) | Назальный противовоспалительный гель на пектиновой основе | |
| JPH0782155A (ja) | グリチルリチン酸直腸製剤 | |
| JP2002370977A (ja) | 局所適用組成物 | |
| HUP0202791A2 (hu) | Pikkelysömör kezelésére alkalmas gyógyszerkészítmények |